Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07123350 · ClinicalTrials.gov registry record
Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease
A clinical trial of Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD), sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT07123350: Active study of Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD), sponsored by Vanderbilt University Medical Center.
NCT07123350 is a study of Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD) that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 120 participants, below the 758-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07123350, a study of Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD), is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this retrospective study is to learn about dosing patterns in patients starting subcutaneous vedolizumab administration and patient outcomes after starting subcutaneous administration. Patients with IBD who are starting subcutaneous vedolizumab administration between September 1, 2023, and March 31, 2025, as part of normal patient care, will be retrospectively reviewed and analyzed.
Primary Outcome
Defined as clinical remission assessed and written by provider in the office visit note
Conditions Studied
Interventions
- DRUG Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2026-03-31 |
What the registry record for NCT07123350 still lists
NCT07123350 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 758-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (84% lower).
The record links to 3 conditions, with Ulcerative Colitis (UC) appearing as the primary indexed condition, and to 1 intervention - of which Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care is the first listed.
NCT07123350 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT07123350 about?
NCT07123350 is a clinical study titled "Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease". The goal of this retrospective study is to learn about dosing patterns in patients starting subcutaneous vedolizumab administration and patient outcomes after starting subcutaneous administration. Patients with IBD who are starting subcutaneous vedolizumab administration between September 1, 2023, ...
What is the current status of trial NCT07123350?
This trial is currently active not recruiting. The enrollment target is 120 participants. The study started on 2025-10-16. Estimated completion is 2026-03-31.
What conditions does trial NCT07123350 study?
This clinical trial studies the following conditions: Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD), Crohn's Disease (CD).
What interventions are being tested in trial NCT07123350?
The interventions under investigation include: Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care (DRUG).
Who is sponsoring clinical trial NCT07123350?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07123350 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis (UC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07123350's enrollment target sits among peer trials
120 11th of 17 higher than 6 of 17 other Ulcerative Colitis (UC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis (UC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RECRUITING
-
Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
RECRUITING · Phase 2
-
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants
RECRUITING · Phase 1
-
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
RECRUITING · NA
-
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
RECRUITING · Phase 1
-
Evaluation of the SMART IBD App in Pediatric IBD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI